Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …

Imatinib Mesylate (imatinib) was once hailed as the magic bullet for chronic myeloid
leukemia (CML) and remains a front-line therapy for CML to this day alongside other …

Acute lymphoblastic leukemia (ALL) is one of the deadliest forms of leukemia due to the
bone marrow producing many white blood cells (WBC). ALL is one of the most common …

Many aspects of health and disease are modeled using the abstraction of a" pathway"—a
set of protein or other subcellular activities with specified functional linkages between them …

While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic
phase chronic myeloid leukemia (CP-CML) is well established, less is known about how …

Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor
(TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia …

Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for
chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy …

Metabolic regulation of cancer cell growth via AMP-activated protein kinase (AMPK)
activation is a widely studied strategy for cancer treatment, including leukemias. Recent …

The non-homologous end joining pathway is vital for repairing DNA double-strand breaks
(DSB), with DNA-dependent protein kinase (DNA-PK) playing a critical role. Altered DNA …